bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company’s product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
Gene Therapy Pionee | Bluebird Bio leads in developing treatments for severe genetic diseases, with promising therapies for sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy |
Financial Tightrope | Explore Bluebird Bio's strategy to achieve cash flow breakeven by 2025 amid revenue challenges and a limited financial runway extending to Q1 2025 |
Market Potential | Delve into the company's position in the growing gene therapy sector, balancing innovative treatments against operational hurdles and fierce competition |
Analyst Outlook | Price targets range from $2 to $4, reflecting cautious optimism about Bluebird Bio's product launches and restructuring efforts to improve financial stability |
Metrics to compare | BLUE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLUEPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.3x | −1.2x | −0.6x | |
PEG Ratio | 0.00 | −0.01 | 0.00 | |
Price/Book | −13.2x | 1.1x | 2.6x | |
Price / LTM Sales | 1.4x | 7.6x | 3.1x | |
Upside (Analyst Target) | 154.1% | 160.2% | 53.1% | |
Fair Value Upside | Unlock | 26.0% | 7.5% | Unlock |